These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23821262)

  • 1. Selecting and characterizing drug-resistant hepatitis C virus replicon.
    Vliegen I; Delang L; Neyts J
    Methods Mol Biol; 2013; 1030():93-103. PubMed ID: 23821262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon.
    Aus dem Siepen M; Oniangue-Ndza C; Wiese M; Ross S; Roggendorf M; Viazov S
    Virus Res; 2007 Apr; 125(1):109-13. PubMed ID: 17254660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
    Verbinnen T; Jacobs T; Vijgen L; Ceulemans H; Neyts J; Fanning G; Lenz O
    J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
    Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
    Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.
    Robinson M; Tian Y; Pagratis N; Delaney WE
    Curr Protoc Microbiol; 2011 Aug; Chapter 17():Unit17.7. PubMed ID: 21805689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.
    Goto K; Watashi K; Inoue D; Hijikata M; Shimotohno K
    Cancer Sci; 2009 Oct; 100(10):1943-50. PubMed ID: 19659609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells.
    Liang C; Rieder E; Hahm B; Jang SK; Paul A; Wimmer E
    Virology; 2005 Mar; 333(1):41-53. PubMed ID: 15708591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.
    Huang P; Goff DA; Huang Q; Martinez A; Xu X; Crowder S; Issakani SD; Anderson E; Sheng N; Achacoso P; Yen A; Kinsella T; Darwish IS; Kolluri R; Hong H; Qu K; Stauffer E; Goldstein E; Singh R; Payan DG; Lu HH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1419-29. PubMed ID: 18227176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.
    O'Boyle DR; Nower PT; Sun JH; Fridell R; Wang C; Valera L; Gao M
    J Virol Methods; 2013 Oct; 193(1):68-76. PubMed ID: 23684844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
    Vijgen L; Verbeeck J; Van Kerckhove B; Berke JM; Koletzki D; Fanning G; Lenz O
    Methods Mol Biol; 2013; 1030():105-17. PubMed ID: 23821263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro anti-hepatitis C virus (HCV) resistance selection and characterization.
    Mo H
    Curr Protoc Pharmacol; 2011 Jun; Chapter 13():Unit 13B.5. PubMed ID: 21935899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
    Pfeiffer JK; Kirkegaard K
    J Virol; 2005 Feb; 79(4):2346-55. PubMed ID: 15681435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells.
    Delang L; Scheers E; Grabner M; Verpaalen B; Helsen N; Vanstreels E; Daelemans D; Verfaillie C; Neyts J
    Biochem Pharmacol; 2015 Aug; 96(3):190-201. PubMed ID: 26070251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
    Sarrazin C; Zeuzem S
    Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.